Acorda Therapeutics, Inc.

In 2002, PAION UK LIMITED (formerly CeNeS Limited) and Acorda Therapeutics, Inc. signed an agreement concerning the development and marketing of recombinant GGF2 (rh GGF2). Acorda is clinically developing GGF2, a neuregulin, for the treatment of heart failure.

 

The agreement gives Acorda the exclusive license to develop, produce and market GGF2. In return, PAION will receive milestone payments prior to approval and one additional milestone payment upon approval. Subsequently, PAION will receive additional royalties depending on net sales.


Additional information is available on Acorda‚Äôs website http://www.acorda.com/